FPR2 and glioblastoma: Considering that HN could reach the tumor from neighboring cells, such as astrocytes [50], or even arrive to the tumor from the general circulation, local blockade of FPR2 using gene therapy vectors encoding for specific shRNA, or for the peptidic antagonist WRW4, could be useful strategies to inhibit this pathway in GBM (Figure 8).